Abstract CT016: Feasibility and efficacy of perioperative nivolumab with or without relatlimab for patients with potentially resectable hepatocellular carcinoma
Hui Li, Sarah M. Shin, Anne M. Noonan, Chester Kao et autres
Abstract Background: Most patients with hepatocellular carcinoma (HCC) experience recurrence after curative-intent resection, highlighting the need for effective perioperative therapies. Neoadjuvant immunotherapy has shown feasibility and pathological changes in clinical trials of early-stage HCC. Here, we evaluate the feasibility of perioperative nivolumab …
us, se (code pays fourni par la source)
1 citation
Cancer Research